Tuberculosis Chemotherapeutics
| Overview |
|---|
- Several structurally-diverse pharmacological therapeutics exist which specifically inhibit Mycobacterium tuberculosis. Resistant strains of this hardy organism emerge within a single patient during monotherapy; therefore, multi-agent therapy for extended periods of time is required for successful elimination of M. tuberculosis. The primary concern with many tuberculosis chemotherapeutics is hepatotoxicity; therefore, serum aminotransferases should be monitored regularly during the extended therapy.
| Member Drugs |
|---|